Q3 2025 10X Genomics Inc Earnings Call Transcript

Nov 6, 2025 / 09:30 PM GMT

Release Date Price: €11.53 (-0.26%)

Transcript 10-Q8-K

Key Points

Positve

10x Genomics Inc (TXG) exceeded the top end of their guidance range with total revenue of $149 million for Q3 2025.
Spatial consumables experienced double-digit year-over-year revenue growth, driven by strong demand for Xenium consumables.
The company ended the quarter with $482 million on the balance sheet, reflecting strong cost management and cash generation.
The launch of the next generation of Chromium Flex assay is expected to enhance scalability and reduce costs, supporting AI-driven initiatives.
10x Genomics Inc (TXG) has formed a partnership with Anthropic to address data analysis bottlenecks, making analysis more accessible to researchers.

Negative

Total revenue for the third quarter was down 2% year-over-year, indicating some challenges in maintaining growth.
Chromium consumables revenue decreased by 4%, primarily due to lower average selling prices.
Total instrument revenue was down 37%, with both Chromium and spatial instrument revenues experiencing significant declines.
The company's gross margin decreased to 67% from 70% the prior year, driven by changes in product mix and higher inventory write-downs.
There is ongoing uncertainty in the US academic and government funding environment, impacting revenue in the Americas.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

TXG.OQ - 10X Genomics Inc
Q3 2025 10X Genomics Inc Earnings Call
Nov 06, 2025 / 09:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Thank you for standing by. Welcome to the 10x Genomics 3rd quarter 2025 earnings conference call.

All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question-and-answer session. If you would like to ask a question during this time, simply press the star, followed by the number one on your telephone keypad. If you would like to reploy your question, please press the star one again.

Thank you. I would now like to turn the conference over to Cassie Cerne, senior director, Investor relations and a strategic finance. You may begin.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.